Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alcon AG (ALC) vs Nutanix Inc (NTNX) Price & Performance

Alcon AG
Nutanix Inc

Price performance

Price movement over the last 24 hours

Key statistics

Alcon AG vs Nutanix Inc — how do they compare? Alcon AG trades at $66.88 (market cap $32.69B), while Nutanix Inc trades at $53.33 (market cap $14.53B). The key difference: Alcon AG is far larger — about 2.2× Nutanix Inc's market cap, and Alcon AG pays a 0.54% dividend while Nutanix Inc pays none. Which is the better fit depends on your goals.

ALCNTNX
Market Cap
$32.69B$14.53B
Sector
HealthTechnology
52-Week High
$92.22$81.12
52-Week Low
$62.02$34.41
Enterprise Value
$36.28B$14.04B
Dividend Yield
0.54%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alcon AG

ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.

The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.

Nutanix Inc

Nutanix (NTNX) trades at $52.42, up 2.22% with strong technical momentum and bullish analyst sentiment. The company demonstrates robust fundamentals with Q3 2026 earnings beating expectations, 87% gross margins, and projected revenue growth to $2.7B in 2026. Recent NVIDIA certification for Unified Storage and expanding enterprise partnerships highlight strategic positioning in hybrid cloud infrastructure.

Outlook remains positive with 62.5% analyst buy ratings and $56.55 consensus target, though elevated P/E ratio of 55.17 and RSI near overbought levels suggest near-term consolidation risk. Key catalysts include AI infrastructure adoption and VMware migration opportunities, while execution risks and competitive pressures require monitoring.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Alcon AG

Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.

Read more on ALC

About Nutanix Inc

Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.

Read more on NTNX